Screener
BioCryst Pharmaceuticals BCRX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalents.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's restricted cash?
- BioCryst Pharmaceuticals (BCRX) reported restricted cash of $1.41M in Q2 2026.
- How has BioCryst Pharmaceuticals's restricted cash changed year-over-year?
- BioCryst Pharmaceuticals's restricted cash increased by 187.0% year-over-year, from $492K to $1.41M.
- What is the long-term trend for BioCryst Pharmaceuticals's restricted cash?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's restricted cash has grown at a -6.3% compound annual growth rate (CAGR), from $2.22M to $1.6M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about BioCryst Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude